Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Vertex rev. argent. psiquiatr ; 24(109): 194-205, 2013 May-Jun.
Article in Spanish | LILACS, BINACIS | ID: biblio-1176906

ABSTRACT

In the present article we will show the results of the workshop known as The First Training Psychiatrists Latin-American Meeting (2012). We will explore as well, the impact of the psychiatric practice on young physicians who look to the specialty. In this article we intend to update existing bibliography on the subject, and share the results of two research studies done by this team: a questionnaire conducted to first year medical residents working in Metropolitan Buenos Aires (2008/9) and a workshop carried out with the participants of the Latin- American meeting mentioned above.


Subject(s)
Psychiatry/education , Education, Medical/standards , Humans
2.
Vertex rev. argent. psiquiatr ; 19(77): 512-521, ene.- feb. 2008. tab
Article in Spanish | LILACS | ID: lil-539679

ABSTRACT

El objetivo de la presente actualización farmacológica es abordar la problemática de la dependencia alcohólica. Partiendo de las bases biológicas y del impacto del etanol sobre los sistemas neurobiológicos y de neurotransmisión, se hará una revisión de las principales herramientas farmacológicas para el tratamiento de la dependencia alcohólica. El disulfiram, la naltrexona y el acamprosato, todas ellas con aprobación por la FDA (Food and Drug Administration) han mostrado mecanismos de acción, perfiles de eficacia, tolerabilidad y adherencia dispares. También nos referiremos al topiramato, el que está siendo estudiado actualmente con relación a esta indicación.


The aim of the present pharmacological update is to revise the problem of alcohol dependence. Starting from the biological bases and the impact of alcohol on the neurobiological and neurotransmission systems, a revision of the main pharmacological tools for alcohol dependence treatment will be done. Disulfiram, naltrexone, acamprosate, all of them approved by the FDA (Food and Drug Administration), have shown mechanisms of action, efficacy, tolerance and adherence dissimilar. We will also refer to topiramate, which is being studied for this indication.


Subject(s)
Humans , Alcoholism/rehabilitation , Alcohol Deterrents/therapeutic use , Disulfiram/therapeutic use , Fructose/analogs & derivatives , Naltrexone/therapeutic use , Taurine/analogs & derivatives , Alcohol Deterrents/adverse effects , Disulfiram/adverse effects , Fructose/adverse effects , Fructose/therapeutic use , Naltrexone/adverse effects , Taurine/adverse effects , Taurine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL